A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

* Male or female, 18 years of age or older. * Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. * May have received prior immunotherapy (including monoclonal antibodies) or vaccine therapies. * Measurable disease, according to RECIST criteria. * Negative pregnancy test (women of childbearing potential only). * Pretreatment laboratory levels that meet specific criteria.

* Prior treatment with Volociximab (M200) or inhibitors of α5β1 integrin (antibodies or small molecules) or gemcitabine and other chemotherapeutic regimens. * Known hypersensitivity to murine proteins or chimeric antibodies or other components of the product. * Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer). * Monoclonal antibody therapy within 4 weeks of the first dose of Volociximab. * Central Nervous System (CNS) tumor or metastasis. * History of bleeding disorders within the past year. * Medical conditions that may be exacerbated by bleeding.